Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | CCNT1 | O60563 | 9/20 | 0.39 |
| ▸ | CDK9 | P50750 | 9/20 | 0.39 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.36 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8120674 | 0.90 | CCNT1 (0.40) | SCN9ACCNT1CDK9CREBBP | |
| SCHEMBL14287083 | 0.88 | CCNT1 (0.37) | KDM4ESCN9ACCNT1CDK9CREBBP | |
| SCHEMBL14422908 | 0.88 | GAA (0.40) | KDM4ESCN9ACCNT1CDK9CREBBP | |
| SCHEMBL14287169 | 0.88 | SCN9A (0.37) | KDM4ESCN9ACCNT1CDK9CREBBP | |
| SCHEMBL3024239 | 0.87 | CCNT1 (0.36) | KDM4ESCN9ACCNT1CDK9CREBBP | |
| SCHEMBL8111928 | 0.87 | CCNT1 (0.36) | KDM4ESCN9ACCNT1CDK9CREBBP | |
| SCHEMBL3013040 | 0.87 | CCNT1 (0.36) | KDM4ESCN9ACCNT1CDK9CREBBP | |
| SCHEMBL14287306 | 0.87 | CCNT1 (0.42) | KDM4ESCN9ACCNT1CDK9CREBBP | |
| SCHEMBL14287072 | 0.86 | KDM4E (0.38) | KDM4ECCNT1CDK9TSHRL3MBTL1 | |
| SCHEMBL6609831 | 0.82 | MCHR1 (0.39) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2009-10-01 | — | — | US | disclosed |
| WO-2008144931-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | PAINCEPTOR PHARMA CORPORATION (CA) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090246134-A1 | COMPOSITIONS AND METHODS FOR MODULATING GATED ION CHANNELS | ASIC1, ASIC3, TRPV1 | KDM4E 3297/4885SCN9A 108/4885CCNT1 4864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.